Improvement roles of methotrexate and mifepristone in serum β-HCG levels, pelvic mass and adverse reactions of patients with ectopic pregnancy

Abstract

Objective To evaluate the improvement roles of methotrexate and mifepristone in serum β-HCG levels, pelvic mass and adverse reactions of patients with ectopic pregnancy. Methods Eighty patients with ectopic pregnancy from May 2014 to May 2016 were selected, these patients were divided into methotrexate and mifepristone treatment group (combined treatment group, n=40) and methotrexate alone group (monotherapy group, n=40) according to the random number table, the serum β-HCG levels, pelvic mass sizes and adverse events of the two groups were statistically analyzed. Results The serum β-HCG levels of the combined treatment group were significantly lower (P<0.05), the pelvic mass was significantly less (P<0.05), the serum β-HCG clearance time, pelvic mass disappearance time, abdominal pain time, stop time of vaginal bleeding was significantly shorter (P<0.05), the total treatment effective rate (95.0%, 38/40) was significantly higher than those of the monotherapy group (75.0%, 30/40), P<0.05. Conclusions Methotrexate and mifepristone can effectively reduce serum β-HCG levels of patients with ectopic pregnancy, reduce pelvic mass, and withouse increase the adverse reactions in a greater degree. Key words: Methotrexate and mifepristone; Ectopic pregnancy; Serum β-human chorionic gonadotropin; Pelvic mass; Adverse reactions; Improvement role